Scotiabank raises Eli Lilly price target to $1605, keeps Sector Outperform
Scotiabank kept its Sector Outperform rating on Eli Lilly and lifted its price target to $1605 from $1300, according to TradingView citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Scotiabank kept its Sector Outperform rating on Eli Lilly and raised its price target by 23.5%, to $1605 from $1300. According to TradingView, which cites Benzinga data, the new target implies 16.8% upside from the October 29 close of $1373.70.
Over the past 30 days, the five latest analyst notes on the stock carry targets between $1500 and $1612. Morgan Stanley has Overweight at $1596, Wells Fargo Overweight at $1500, Truist Securities Buy at $1612, RBC Capital Outperform at $1600 and Argus Research Buy at $1550.
why it matters
Notes like this reflect one analyst's view and usually have limited impact on the broader market. Investors often look at the consensus across brokers, and in this set the targets sit well above the October 29 close.
tags
instruments
sources
- Scotiabank maintains Eli Lilly at Sector Outperform, raises price target to $1605 from $1300 — TradingView, 30 October 2026 at 18:54 UTC
- Scotiabank maintains AltaGas at Sector Outperform, raises price target to $63 from $61 — TradingView, 30 October 2026 at 19:39 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗